TLR9 and sarcoma: In contrast, in the p53/MCA model, we did not observe substantial changes in the intratumoral CD4+ T cell population after combination of CpG+RT, suggesting potential differences in immune-activation mechanisms between TLR4 and TLR9 pathways (Figure 3E and Figure 5B) and/or differences in the mouse model and human sarcomas.